| 纯度 | >90%SDS-PAGE. |
| 种属 | E.col |
| 靶点 | mrkA |
| Uniprot No | P12267 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-202aa |
| 氨基酸序列 | ADTNVGGGQVNFFGKVTDVSCTVSVNGQGSDANVYLSPVTLTEVKAAAADTYLKPKSFTIDVSDCQAADGTKQDDVSKLGVNWTGGNLLAGATAKQQGYLANTEAAGAQNIQLVLSTDNATALTNKIIPGDSTQPKAAGDASAVQDGARFTYYVGYATSTPTTVTTGVVNSYATYEITYQ |
| 预测分子量 | 20.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于mrkA重组蛋白的3篇参考文献示例(文献信息为假设性示例，实际需根据具体研究补充)：
---
1. **文献名称**: *"Functional characterization of MrkA in Klebsiella pneumoniae biofilm formation"*
**作者**: Struve C., et al.
**摘要**: 研究通过重组表达MrkA蛋白，验证其在肺炎克雷伯菌III型菌毛介导的宿主细胞黏附及生物膜形成中的关键作用，证实MrkA缺失显著降低细菌致病性。
2. **文献名称**: *"Recombinant MrkA as a vaccine candidate against Klebsiella infections"*
**作者**: Murphy C.N., et al.
**摘要**: 评估重组MrkA蛋白的免疫原性，动物实验表明其能诱导保护性抗体，降低肺部感染模型中肺炎克雷伯菌的定植率，提示其作为疫苗靶点的潜力。
3. **文献名称**: *"Structural insights into MrkA-mediated bacterial aggregation"*
**作者**: Langstraat J., et al.
**摘要**: 利用重组MrkA蛋白进行X射线晶体学分析，揭示其黏附结构域的关键氨基酸残基，阐明其通过寡聚化介导细菌聚集的分子机制。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词 **"mrkA recombinant protein"** 或 **"Klebsiella pneumoniae type 3 fimbriae"**，并筛选近年研究。
The MrkA protein is a key structural component of type 3 fimbriae in *Klebsiella pneumoniae*, a Gram-negative pathogen associated with hospital-acquired infections such as pneumonia, urinary tract infections, and bloodstream infections. These hair-like appendages mediate bacterial adhesion to host surfaces, particularly to extracellular matrix components like collagen, and contribute to biofilm formation on abiotic surfaces (e.g., medical devices). The *mrkA* gene is part of the *mrkABCD* operon, which is regulated by environmental conditions and linked to bacterial virulence.
Recombinant MrkA (rMrkA) is produced via genetic engineering, typically by cloning the *mrkA* gene into expression vectors (e.g., *E. coli* systems) to enable large-scale protein synthesis. Purified rMrkA retains its functional properties, allowing researchers to study its role in host-pathogen interactions, immune evasion, and biofilm dynamics. Structurally, MrkA contains conserved domains critical for fimbrial assembly and receptor binding, making it a target for antibody development or inhibitor design.
Studies using rMrkA have highlighted its immunogenicity, suggesting potential as a vaccine candidate or diagnostic antigen. Additionally, disrupting MrkA-mediated adhesion could mitigate *K. pneumoniae* virulence, offering therapeutic avenues. Research on rMrkA also extends to understanding antibiotic resistance mechanisms, as biofilms harboring *Klebsiella* often exhibit enhanced tolerance to antimicrobial agents. Overall, rMrkA serves as a vital tool for unraveling bacterial pathogenesis and developing targeted interventions against multidrug-resistant *K. pneumoniae* strains.
×
